l really do not see the upside for Arrow, as they have already been marketing Sigma products and have a far superior sales team. In time Arrow would dwarf Sigma as its sales are increasing exponentially higher.
l also note around 5 mil in performance options which rather dwarfs the 2 - 3 mil in synergism savings. Seeems that directors will take quick profits and move along. Certainly see AWP with lower growth in the future. Cannot justify PE of 39 ! Looks like PE of 24 coming up
AWP
arrow pharmaceuticals limited
l really do not see the upside for Arrow, as they have already...
Add to My Watchlist
What is My Watchlist?